Key facts
- It has raised $44.2M; the latest was Accelerator/Incubator in Oct 2024.
- Notable investors include Novo Holdings, Industrifonden, Nordic Mentor Network For Entrepreneurship, 3B Future Health Fund, EIC Scaling Club — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for AnaCardio
- ·The full record, as it builds
Funding rounds
No funding rounds for AnaCardio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AnaCardio
Developer of therapeutic drugs designed to improve clinical outcomes in cardiac failure. The company's drugs improve the contractility of the heart muscle through a differentiated mechanism using a therapeutic peptide without causing adverse tachycardia, arrhythmia, ischemia, or hypotension, enabling medical professionals to provide safe cardiac output in human heart failure which can potentially improve organ function, quality of life and functional capacity, and reduce the risk of hospitalization and death.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2017
- Employees
- 11
- Website
- anacardio.com/
- Ownership
- Privately Held (backing)
AnaCardio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AnaCardio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AnaCardio in its N-PORT filings yet. We sweep new filings monthly.